With AI expected to play a significant role in drug approvals, how can companies build data sets that are ready for AI?

Currax Pharmaceuticals expands its impactful campaigns, showcasing real patient stories to empower those battling obesity and food cravings across the U.S.

Gene Mack, CEO, Gain Therapeutics, explains how the company’s Magellan AI platform analyzes novel protein binding sites to identify and design drug candidates beyond what’s currently available in the ...

It’s a bad time to try to predict future pharmaceutical prices.

Celltrion's Avtozma IV gains FDA approval for treating cytokine release syndrome, enhancing treatment options for patients aged 2 and older.

Ajovy becomes the first-and-only calcitonin gene-related peptide agonist approved for pediatric patients aged six to 17 years ...

The deal brings the FDA-approved neuroblastoma therapy Danyelza (naxitamab-gqgk) to SERB Pharmaceuticals and advances its ...

HHS is winding down mRNA vaccine development, impacting contracts with major pharma companies and resulting in nearly $500 ...

The Regeneron litigation highlights that donations routed through independent entities are not immune from challenge, especially if the government believes they are effectively covering a patient’s co ...

By using real-world data (RWD) and the insights derived from it, real-world evidence (RWE) earlier in research and ...

Explore how Wounded Warrior Project and advocates like Morgan Fox promote mental health awareness and support for veterans ...

Pharmaceutical Executive delivers strategic insights for pharma leaders, covering commercialization, market access, R&D, and leadership to drive success.